ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology …
Writing Committee Members, EM Antman, DT Anbe… - Circulation, 2004 - Am Heart Assoc
D. Medication Assessment............................................ 610 1. Beta Blockers....................................
................. 609 2. Nitroglycerin...................................................... 610 3. Inhibition of the Renin …
................. 609 2. Nitroglycerin...................................................... 610 3. Inhibition of the Renin …
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
S Julius, SE Kjeldsen, M Weber, HR Brunner, S Ekman… - The Lancet, 2004 - thelancet.com
Summary Background The Valsartan Antihypertensive Long-term Use Evaluation (VALUE)
trial was designed to test the hypothesis that for the same blood-pressure control, valsartan …
trial was designed to test the hypothesis that for the same blood-pressure control, valsartan …
Chronic kidney disease: effects on the cardiovascular system
EL Schiffrin, ML Lipman, JFE Mann - Circulation, 2007 - Am Heart Assoc
Accelerated cardiovascular disease is a frequent complication of renal disease. Chronic
kidney disease promotes hypertension and dyslipidemia, which in turn can contribute to the …
kidney disease promotes hypertension and dyslipidemia, which in turn can contribute to the …
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart …
SC Smith Jr, J Allen, SN Blair, RO Bonow, LM Brass… - Circulation, 2006 - Am Heart Assoc
• Ask about tobacco use status at every visit. I (B)• Advise every tobacco user to quit. I (B)•
Assess the tobacco user's willingness to quit. I (B)• Assist by counseling and developing a …
Assess the tobacco user's willingness to quit. I (B)• Assist by counseling and developing a …
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline …
KS Jering, B Claggett, MA Pfeffer… - European journal of …, 2021 - Wiley Online Library
Aims Patients surviving an acute myocardial infarction (AMI) are at risk of developing
symptomatic heart failure (HF) or premature death. We hypothesized that …
symptomatic heart failure (HF) or premature death. We hypothesized that …
Medical therapy for heart failure caused by ischemic heart disease
IY Elgendy, D Mahtta, CJ Pepine - Circulation research, 2019 - Am Heart Assoc
Patients with heart failure (HF) syndromes have been categorized as those with reduced
ejection fraction (EF) or preserved EF (HFpEF), and ischemia plays a key role in both types …
ejection fraction (EF) or preserved EF (HFpEF), and ischemia plays a key role in both types …
[HTML][HTML] Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
NS Anavekar, JJV McMurray… - … England Journal of …, 2004 - Mass Medical Soc
Background The presence of coexisting conditions has a substantial effect on the outcome
of acute myocardial infarction. Renal failure is associated with one of the highest risks, but …
of acute myocardial infarction. Renal failure is associated with one of the highest risks, but …
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
MA Konstam, JD Neaton, K Dickstein, H Drexler… - The Lancet, 2009 - thelancet.com
Summary Background Angiotensin-receptor blockers (ARBs) are effective treatments for
patients with heart failure, but the relation between dose and clinical outcomes has not been …
patients with heart failure, but the relation between dose and clinical outcomes has not been …
A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation
JR Erickson, AJ Mei-ling, X Guan, W Kutschke, J Yang… - Cell, 2008 - cell.com
Summary Calcium/calmodulin (Ca 2+/CaM)-dependent protein kinase II (CaMKII) couples
increases in cellular Ca 2+ to fundamental responses in excitable cells. CaMKII was …
increases in cellular Ca 2+ to fundamental responses in excitable cells. CaMKII was …
[HTML][HTML] Effect of valsartan on the incidence of diabetes and cardiovascular events
NAVIGATOR Study Group - New England Journal of Medicine, 2010 - Mass Medical Soc
Background It is not known whether drugs that block the renin–angiotensin system reduce
the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance …
the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance …